<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869400</url>
  </required_header>
  <id_info>
    <org_study_id>OvaYond</org_study_id>
    <nct_id>NCT01869400</nct_id>
  </id_info>
  <brief_title>An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer</brief_title>
  <acronym>NIS-OvaYond</acronym>
  <official_title>An Observational, Multicenter, Open-label Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar, Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trials are, due to the inclusion and exclusion criteria, accomplished with defined
      patient groups, which are not representative for the whole patient population.

      Especially elderly patients and patients with co-morbidities are underrepresented in clinical
      trials.

      This non-interventional study will examine the efficiency and toxicity of the Yondelis® + PLD
      combination therapy in a general patient population to evaluate if the data collected in the
      clinical trials can be assigned to a general patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Yondelis® (trabectedin) was approved (in combination with PLD) in the European community in
      December 2009 for the treatment of platinum-sensitive ovarian cancer relapse. Based on the
      outcomes of study OVA-301, this non-interventional study will investigate the role of a
      platinum-free treatment regimen in patients with progressive ovarian cancer relapsing &gt; 6
      months after completing previous platinum-based chemotherapy. In particular, this study aims
      at collecting the &quot;real-life&quot; data with regard to the response and the influence of the
      mentioned therapy on the &quot;tumor related events&quot;, to objectify the value of palliative care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability data of the study therapy</measure>
    <time_frame>during Yondelis-PLD-therapy</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;Real life data&quot; - clinical and / or serological (CA 125) response and Stable disease rates</measure>
    <time_frame>till one year after last date of Yondelis-PLD-therapy</time_frame>
    <description>Number of patients with CR, PR, SD as best response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>during Yondelis-PLD-therapy</time_frame>
    <description>Time between first and last cycle of each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observation of the number of the therapy cycles applied</measure>
    <time_frame>during Yondelis-PLD-therapy</time_frame>
    <description>Number of applied therapy cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>1 Year after last Yondelis-PLD-Therapy</time_frame>
    <description>Date from last Yondelis-PLD-treatment to date of next treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>till one year after last date of Yondelis-PLD-therapy</time_frame>
    <description>Difference between date of first documentation of &quot;PD&quot; and the date of first Yondelis® + PLD application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>till one year after last date of Yondelis-PLD-therapy</time_frame>
    <description>Time in months from first assessment of CR or PR until the first date of PD or death.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Yondelis-Pegylated liposomal Doxorubicin</arm_group_label>
    <description>30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        hospitales and medical practices in Germany
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age &gt;18, no upper limit

          -  Patients with relapsed platinum-sensitive ovarian cancer

          -  Before inclusion in the NIS written informed consent must be given

        Exclusion Criteria:

          -  According to summary of product characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingo Runnebaum, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Frauenheilkunde, Bachstr. 18, D-07743 Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis und Tagesklinik für gynäkologische Onkologie</name>
      <address>
        <city>Ebersberg</city>
        <state>Bayern</state>
        <zip>85567</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus, Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Rotenburg</city>
        <state>Lower Saxony</state>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

